Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 168,800 shares, a decrease of 5.9% from the October 31st total of 179,400 shares. Approximately 18.0% of the shares of the company are short sold. Based on an average daily trading volume, of 589,300 shares, the short-interest ratio is presently 0.3 days.

Allarity Therapeutics Stock Down 0.9 %

Shares of NASDAQ:ALLR opened at $1.09 on Monday. The stock’s 50-day moving average is $1.54 and its 200-day moving average is $6.01. Allarity Therapeutics has a 52-week low of $1.09 and a 52-week high of $666.00.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.